The Medicines Company To Present Data At ASM Microbe 2017 On Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and late-stage product candidates will be featured in presentations at the American Society for Microbiology’s ASM Microbe 2017 to be held June 1-5, 2017 in New Orleans. The Medicines Company’s infectious disease research and product development is focused on the most serious multi-drug resistant infections, including carbapenem-resistant Enterobacteriaceae (CRE).

The Company will present data on its investigational antibiotic, meropenem-vaborbactam, from the TANGO 1 Phase III trial that compared it to piperacillin-tazobactam in the treatment of complicated urinary tract infections (cUTIs). Additional data on meropenem-vaborbactam’s in vitro activity against clinical isolates of carbapenem-resistant Enterobacteriaceae, and in experimental treatment models will also be presented. Data from studies of the Company’s marketed products Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection will also be presented.

“ASM Microbe 2017 will display cutting-edge science and the latest developments in the field of microbiology and clinical trials of antibiotics. The Medicines Company is pleased to demonstrate its strong commitment to advancing the discovery and development of innovative antimicrobial drugs for pathogens that The World Health Organization recently identified as a critical need,” said Michael Dudley, PharmD, FIDSA, Senior Vice President, Head of R&D and Co-Leader of The Medicines Company’s Infectious Disease Business.

Tony Kingsley, President and Chief Operating Officer of The Medicines Company, added, “The research presented at ASM Microbe further showcases The Medicines Company’s fully-integrated infectious disease franchise. We are a biopharmaceutical company with capabilities from discovery to commercialization and are tackling major multi-drug resistant antibacterial threats which we also believe represent attractive global market opportunities. We are committed to growing this focused, effective, and fully-integrated infectious disease business.”

The American Society for Microbiology’s ASM Microbe 2017, showcases the best microbial sciences in the world, and provides a one-of-a-kind forum to explore the complete spectrum of microbiology from basic science to translation and application. Details of The Medicines Company’s presentations are provided below. The complete program of titles, abstracts, and electronic versions of posters can be accessed on the ASM Microbe 2107 website at https://www.asm.org. All times listed below are in Central Daylight Time.

Back to news